echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > New Gene Therapy for the Treatment of Common Alzheimer's Disease Completes US$80 million in Series A Financing

    New Gene Therapy for the Treatment of Common Alzheimer's Disease Completes US$80 million in Series A Financing

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, AviadoBio announced the completion of a US$80 million Series A financing


    Frontotemporal dementia is the second most common senile dementia after Alzheimer's disease, and there is currently no approved treatment


    Note: The original text has been deleted

    Reference materials:

    [1] AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform.


    [2] Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies.


    [3] Gene therapy startup bursts forth from incubation at J&J and F-Prime, graduating with $80M and a Novartis veteran at the helm.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.